Commercial dependence on Attruby and Beyonttra
The company states its business is substantially dependent on the commercial success of these products.
- Scope
- Revenue concentration and launch execution
- Materiality
- high
BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company built around a portfolio model for genetic diseases. The company discovers, develops, and commercializes medicines aimed at patients with significant unmet medical needs, using a decentralized structure that lets it run multiple programs in parallel. Its first commercial product, Attruby (acoramidis), launched in the United States in late 2024, while Beyonttra was approved in Europe and Japan in 2025. Beyond its marketed products, BridgeBio has a late-stage pipeline that includes programs in achondroplasia, limb-girdle muscular dystrophy type 2I/R9, and autosomal dominant hypocalcemia type 1.
−103,2 %
95,8 %
−146,0 %
+126,3 %
2.77
2.68
| % | |
|---|---|
| Commercial products | 35% Approved medicines sold directly or through partners, including Attruby and Beyonttra. |
| License and collaboration revenue | 55% Upfront payments, regulatory milestones, sales milestones, and royalties from licensing deals such as Bayer. |
| Clinical-stage pipeline | 0% Internal research and development programs advancing genetic-disease candidates toward approval. |
| Commercial supply and services | 10% Manufacturing and supply of product for partners under commercial supply agreements. |
BridgeBio sells primarily to patients through the healthcare system, but its direct commercial counterparties also...
- Rare disease patientsprimary
Patients with genetic diseases such as transthyretin amyloidosis who receive the approved medicines.
- Specialist physicians and treatment centersprimary
Cardiology, genetics, neurology, and other specialists who diagnose patients and prescribe BridgeBio therapies.
- Pharmaceutical partnersprimary
Partners like Bayer that license acoramidis in defined territories and pay milestones, royalties, and supply revenue.
- Payors and reimbursement authoritiessecondary
Insurers and national health systems that influence uptake through coverage, pricing, and formulary access.
- Clinical research sitessecondary
Hospitals and investigators that enroll patients in late-stage studies for BridgeBio's pipeline programs.
BridgeBio is headquartered in the United States and generates commercial revenue there through Attruby, while also...
- •United States is the core commercial market for Attruby
- •European Union and EPO member states are licensed to Bayer
- •Japan is an approved market for Beyonttra
- •BridgeBio may use partners and distributors outside the U.S.
- •Third-party CMOs support supply for U.S. and ex-U.S. sales
- •Geographic expansion is partnership-led rather than fully owned
BridgeBio's strategy is to run a portfolio of genetically targeted programs through a decentralized hub-and-spoke model...
01
Commercialize Attruby in the U.S.short-term
The first wholly owned commercial product is the main direct revenue engine and validates the platform.
02
Advance late-stage pipeline programs to regulatory submissionmedium-term
New approvals are needed to diversify revenue beyond the first commercial asset.
03
Expand through partnerships outside the U.S.medium-term
Partner-led commercialization reduces the need for a large direct international sales force.
04
Maintain a capital-efficient portfolio operating modellong-term
The company depends on disciplined allocation of capital across many programs and subsidiaries.
BridgeBio is highly exposed to the commercial performance of Attruby and Beyonttra, so slower-than-expected physician...
Manufacturing disruption or CMO underperformance
BridgeBio does not own manufacturing facilities and relies on third parties for raw materials, drug substance, drug product, and packaging.
- Scope
- Supply continuity, margins, launch timing
- Materiality
- high
Single-source supplier dependence
Loss of a single-source supplier could materially and adversely affect product supply and development timelines.
- Scope
- Clinical and commercial supply
- Materiality
- high
Regulatory approval and compliance risk
Pipeline value depends on successful FDA and other agency approvals, and promotion rules can limit commercialization practices.
- Scope
- Pipeline conversion and launch execution
- Materiality
- high
Market access and payer acceptance
Rare-disease adoption depends on physician, patient, and payor acceptance, which can be slow or uneven.
- Scope
- U.S. and ex-U.S. uptake
- Materiality
- medium
Revenue recognition for licensing and collaboration agreements
Can cause large quarterly fluctuations in license and services revenue
Commercial launch revenue recognition
Affects net product revenue and launch comparability
Consolidation of controlled entities
Can materially change reported revenue, expenses, and leverage
Estimates for financing and royalty arrangements
Influences reported financing costs and balance sheet obligations
BridgeBio Oncology Therapeutics, Inc.
BBOT · Pharmaceutical Preparations
Rallybio Corp
RLYB · Pharmaceutical Preparations
Rallybio Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for rare diseases with significant unmet medical need.
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
BIOCRYST PHARMACEUTICALS INC
BCRX · Biological Products, (No Diagnostic Substances)
Biocryst Pharmaceuticals is a U.S.-based biotechnology company focused on rare diseases, with its core commercial product ORLADEYO for hereditary angioedema (HAE).
Passage BIO, Inc.
PASG · Biological Products, (No Diagnostic Substances)
Vincerx Pharma, Inc.
Pharmaceutical Preparations
: 11/08/2026